Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Neurochem Int. 2016 Oct 31;107:138–147. doi: 10.1016/j.neuint.2016.10.007

Figure 3. DRα 1-MOG-35-55 treatment reduces number of activated cells and their CD74 surface expression in the ischemic brain 96 hr after MCAO and reverses MCAO-induced splenic atrophy.

Figure 3

A) Absolute lymphocytes numbers in the non-ischemic left and ischemic right brain from DRα1-MOG-35-55-treated versus Vehicle-treated mice. B) CD74 cell surface expression on CD11b+CD45high cells in the right brain. C). Absolute cell numbers in the spleen from DRα1-MOG-35-55-treated versus Vehicle-treated mice; * p<0.05, **p<0.01, ***p<0.001. Reprinted from Metabolic Brain Disease. A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. 29(1):37-45. 2014. Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, Vandenbark AA, Alkayed NJ, Offner H. © Springer Science+Business Media New York 2013. With permission of Springer.